Evidence map›Paper›PMID 42149196›Full record

ReviewUrologie (Heidelberg, Germany)2026

[Clinical and practical aspects of multidrug-resistant pathogens].

Fabian P Stangl, Jennifer Kranz

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fabian P StanglUniversitätsklinik für Urologie und Kinderurologie, Julius-Maximilians-Universität Würzburg, Medizinische Fakultät, Würzburg, Deutschland. fabian.stangl@alumni.pmu.ac.at.
Jennifer KranzKlinik für Urologie und Kinderurologie, Uniklinik RWTH Aachen, Aachen, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug-resistant pathogens are the result of cumulative risk constellations and inappropriate antibiotic use. Multidrug-resistant Gram-negative bacteria are of particular relevance, especially in patients with prior antibiotic therapy, recurrent hospitalization, urinary drainage devices or a high density of invasive procedures. A central element of clinical management is the strict distinction between asymptomatic bacteriuria and clinically manifested urinary tract infections. Antimicrobial therapy is justified exclusively in the presence of a clinically manifested infection and, even in the context of multidrug resistance, must primarily be guided by the severity of the disease and the infection focus. In urology, the diagnostic work-up of multidrug-resistant pathogens primarily serves the risk stratification and treatment planning. Therapeutically, the principle of an initial empirical approach followed by targeted adjustment and de-escalation also applies to infections caused by multidrug-resistant organisms. In the perioperative setting, a known colonization with multidrug-resistant pathogens requires a differentiated, guideline-based risk assessment.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialUrinary Tract InfectionsHumansAnti-Bacterial AgentsAntibiotic stewardshipAntimicrobial therapyESBL-producing EnterobacteralesPerioperative antibiotic prophylaxisUrinary tract infections

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.